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Everything should be made as simple as possible, but no simpler.
- simplified quote by Einstein

Abstract
Evidence-based health policy may require modelling of different interventions.
The choice of model complexity is a trade-off, where simpler models may be
easier to describe and calibrate, while complex models may better represent the
disease dynamics and lead to more valid predictions. Modelling for health policy
is inherently multidisciplinary, with relevant disciplines including epidemiology,
clinical medicine, biostatistics, health economics and computer science.
As a motivation, we sought to assess the cost-effectiveness of a new prostate
cancer screening test – STHLM3. The STHLM3 test uses a combination of
biomarkers and self-reported data for prediction. The STHLM3 test can be used
as a reflex test after a PSA test. To assess the cost-effectiveness, we needed a
model that represents the natural history of prostate cancer. This model was then
used to predict the short- and long-term effects of different prostate cancer
testing interventions.
To achieve this, we developed a framework for event-oriented, discrete event
simulation in R and C++ in Study I. The framework included common random
numbers, which reduces the Monte Carlo error, and detailed in-simulation
reporting for health economic evaluations. In Study II, we extended an older US
prostate cancer model to better model for Gleason score. Model inputs included
PSA testing, prostate cancer diagnosis, treatment, management and survival. The
calibration of the natural history model included both screened and unscreened
populations. We initially calibrated the Swedish "Prostata" model using
maximum likelihood estimation with non-linear equality constraints.
Subsequently in Study IV, we developed a method based on approximate
Bayesian computations and Markov chain Monte Carlo methods. The hybrid
method provided a more systematic approach to incorporate evidence at different
scales while still using known likelihoods. For Study III, we further extended
the calibrated model to include costs, health state values and discounting. We
calculated the life-time expected costs and effectiveness under different test
interventions. We found that the STHLM3 test was cost-effective in Sweden at a
reflex PSA threshold of 2 ng/mL.
For broader conclusions, first, microsimulation is a challenging computational
and scientific task, particularly for calibration and sensitivity analyses. Second,
ironically, the depth of the Swedish health and population registers made it easier
to invalidate complex models that had been well validated in other populations.
The Swedish data can support efforts to improve existing models for cancer
screening and, more broadly, other health interventions.
Strengths of our approach included: a flexible, lightweight, fast, scalable,
open, microsimulation framework for health policy development; calibration of
the natural history model to current incidence by Gleason grading and recent
survival, whereas most other models have been calibrated to older, PSA-naïve
populations; and incorporation of detailed data and estimates, making best use of
the available Swedish health and population registers. Limitations of our
approach include: imprecise estimates for the effect of prostate cancer testing on
mortality; uncertainty in the validity of the natural history model for predictions
outside of observed evidence; and uncertainty in the validity of the health state
values. For future work, we plan to extend the Prostata model to include
magnetic resonance imaging in combination with the newer prostate cancer
screening tests.
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1 Introduction
Prostate cancer is a highly prevalent cancer in older men and the most common cause of
cancer death among Swedish males [1]. Costs due to prostate cancer testing, diagnostics
and treatments are substantial. The large European Randomized study of Screening for
Prostate Cancer (ERSPC) provided evidence that screening using the prostate-specific
antigen (PSA) test could reduce prostate cancer mortality by 20% over 13 years [2].
However, there is uncertainty whether any potential benefits from prostate cancer
screening will outweigh the harms or whether screening will be cost-effective [3]. Due
to these uncertainties, PSA testing is not systematically organised in Sweden.
1.1 Aims of the Thesis
The overall aim was to provide tools and methods to predict costs and effectiveness of
cancer screening in general and prostate cancer screening in Sweden specifically. As an
application, we aimed to investigate the cost-effectiveness of the STHLM3 prostate cancer
screening test.
To achieve this the following studies were performed:
 For Study I, we aimed to describe the design choices in our parallel discrete-event
microsimulation R package for planning cancer screening.
 For Study II, our aim was to adapt and extend an older US model of the natural
history of prostate cancer for the Swedish setting. We calibrated and validated our
model using detailed longitudinal Swedish registry data. The resulting model is
available as an R package called prostata.
 In Study III we used the outcomes from Study I and Study II to investigate the
cost-effectiveness of a novel screening test for prostate cancer.
 In Study IV we wanted to describe an alternative method for calibration,
improving on the calibration that was done in Study II.
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2 Background
2.1 Prostate cancer
Our research relates to the early detection of prostate cancer. The prostate gland is a
male reproductive organ, located around the urethra. The prostate is, together with other
glands, responsible for the production of semen. The risk of developing cancer in the
prostate increases with a man’s age.
Prostate cancer is the most common cancer diagnosis and the most common cause of
cancer death in Sweden, responsible for 33% of male cancer diagnoses and 22% of male
cancer deaths in 2018 [4]. Prostate cancer incidence rates in Sweden are now comparable
to rates in countries that had an early introduction of PSA testing (see Figure 2.1), while
prostate cancer mortality rates in Sweden are higher than in most other countries (see
Figure 2.2) [5].
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Figure 2.1: Age-standardised prostate cancer incidence per 100,000 man-years.
Source: [4]
With over 100,000 prevalent cases in Sweden, the health burden and the costs on the
health care system are substantial [1]. While a number of risk factors have been
proposed for prostate cancer, including diet and occupational exposures, the only factors
conclusively shown to increase risk of the disease are age, ethnicity and family history
[6, 7]. Given the high prevalence of the cancer and limited opportunities for primary
prevention, a good screening1 test would reduce the health burden due to prostate cancer.
1We use "screening" in the general sense of testing in an asymptomatic population.
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Figure 2.2: Age-standardised prostate cancer mortality rates per 100,000 man-
years. Source: [4]
2.1.1 Gleason grade
The Gleason grading system is used by pathologists when assessing histological patterns
in prostate cancer biopsies. The pathologist quantifies the cell morphology with a grade
ranging from one to five. This is then summarised in a total score composed by the
primary grade (i.e. the most common morphological pattern) and a secondary grade. If
the primary grade also is the most severe grade, then the secondary grade is decided by
the second most common pattern (ignoring patterns that occupy less than 5% of the
tumour area). If there are patterns more severe than the primary grade, then the most
severe pattern is used for the secondary grade independent of size. In 2005 the
International Society of Urological Pathology changed the Gleason reporting such that
the lowest reported cancer grade (with "extremely rare exception"), for needle biopsies
was set to Gleason score 3+3 = 6. Patients with a prostate cancers with a Gleason score
≤ 6 usually have better prognosis than patients with a higher Gleason score [8, 9]. The
2005 change was done partly because of changing practices in reporting Gleason
patterns, which had lead to a Gleason score inflation. Since then there have been further
reports on continued Gleason inflation [10]. Changes in Gleason reporting, both through
inflation and altered guidelines, pose a challenge for assessing the long-term prognosis
by Gleason score.
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2.1.2 Staging
The TNM system is used for classifying tumours. The T describes the size or extent of the
tumour, N describes the involvement of lymph nodes and M if there are distant metastasis
or not. For our model, M-staging and T-staging will be of most importance. The T-stages
starts with T0, which indicates no evidence of prostate cancer, and ends with T4, which
means that the tumour has invaded adjacent tissue [11, 12].
2.2 PSA screening
The PSA test was first used to monitor disease progression in prostate cancer patients,
and was later taken up as the de facto screening test for prostate cancer in many countries,
leading to rapid rises in prostate cancer incidence. The test characteristics for the PSA
test in detecting prostate cancer are comparable to those for breast cancer mammography,
with a sensitivity of 72% and a specificity of 93% when using a PSA threshold of 4 ng/ml
[13]. However, the Swedish guidelines recommends a threshold of 3 ng/ml for men below
age 70 years [12], which has led to an increased sensitivity and a reduced specificity [14].
Our group has recently reported that 50–75% of men aged 50 years and over living in
Stockholm have had a PSA test within the last nine years [15].
There is uncertainty in how best to use the PSA test. The ERSPC trial indicated that
PSA testing reduces prostate cancer mortality by around 20% after 13 years of follow-
up [2]. This was, however, not observed in two other large randomised studies. The
results from the Prostate, Lung, Colorectal and Ovarian Study (PLCO) Cancer Screening
Trial in the United States suggest that organised PSA testing has little effect on prostate
cancer mortality in a population where opportunistic testing has already reached high
levels and where there is poor biopsy compliance [16] 1. The recent Cluster Randomized
Trial of PSA Testing for Prostate Cancer (CAP) in the United Kingdom investigated the
effects of a single screen. CAP found that, with 40% attendance at a single clinical visit,
PSA testing lead to a non-significant estimated mortality reduction of 4% after ten years
of follow-up [17].
PSA testing is common in most western countries, even though the balance between
benefits and harms is uncertain [3, 18].
For the Swedish context, the Göteborg site of the ERSPC estimated a large effect size
[19], however there is no statistical evidence for heterogeneity between the ERSPC sites
(p=0.4) [2]. It is however noteworthy, that the mortality rates in the Nordic region are
comparatively high [4], as described in the Prostate cancer section.
1Biopsy compliance is defined as having a biopsy following a positive PSA test.
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2.3 Alternative screening tests
Efforts have been made to improve upon the PSA screening test. This has been suggested
in the form of a reflex test, where a PSA test is first performed and depending on its result
a secondary test may be performed.
The STHLM3 test is a new prostate cancer test based on five plasma protein
biomarkers (including PSA, free PSA, intact PSA, hK2, MSMB and MIC1) and 232
single nucleotide polymorphisms (SNPs) together with clinical variables such as age,
family, history, previous prostate biopsy and prostate examinations. The accuracy of the
STHLM3 test has been reported in The Lancet Oncology [20]. The STHLM3 test
reduced false positive biopsies by 42% and reduced diagnoses of small Gleason score 6
cancers by 17% whilst maintaining sensitivity for cancers with Gleason score 7 and
higher, compared to using PSA ≥ 3ng/mL. Due to the paired screen-positive design of
the study, the corresponding area under the curve (AUC)s can not be directly compared
to AUCs from other risk panels.
Other prediction models for early detection of prostate cancer include the
Four-kallikrein Panel (4K panel), the Prostate Health Index (PHI) and the Prostate
Cancer Antigen 3 (PCA3) test. The 4K panel consists of kallikrein-related peptidase 2
(hK2), intact PSA, and free and total PSA. The four-kallikrein panel has shown an AUCs
of 71.8% when predicting high-grade cancer (Gleason score ≥7). The Prostate Health
Index includes total PSA value, free PSA value, and the PSA isoform [S2]proPSA. The
PHI panel has shown similar AUCs as the 4K panel, with an AUC of 71.1% for detecting
high-grade cancer (Gleason score ≥7) [21]. These panels have been evaluated in
diagnostic trials, however a screening trial would be needed to provide evidence on the
long-term outcomes.
2.4 Prostate cancer models
The Cancer Intervention Surveillance Modeling Network (CISNET) consortium uses
statistical modelling to understand cancer interventions and their effects on incidence
and mortality. CISNET was started in 2000 and includes models for breast, cervical,
colorectal, esophagus, lung, and prostate cancer. Over the years CISNET has made
substantial contributions to understanding the effects of mass screening [22, 23]. A
particularly important contribution is the comparative modelling, where common inputs
and outputs allows for comparisons of model assumptions. CISNET has also been
successful in bringing together data from different data sources, including trial evidence.
The consortium has, however, been constrained by the lack of longitudinal data from US
data sources that are needed to set up and evaluate personalised screening programs. For
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prostate cancer screening there are three microsimulation models used within CISNET,
which were developed by the Erasmus Medical University, the University of Michigan
and the Fred Hutchinson Cancer Research Center (FHCRC), respectively [24].
2.4.1 Erasmus Medical University
The Microsimulation Screening Analysis (MISCAN) program has been in continuous
development at the Erasmus Medical University since the 1980s to model cancer
screening for different cancer sites [25]. For prostate cancer, the cancer related event
history is defined by a sequence of disease states and the ages at which these states are
entered [24]. These life histories are generated by a semi-Markov process. The disease
history are modelled in a preclinical phase and a clinical phase, where the preclinical
phase does not correspond to clinical diagnosis, but the disease can be detected by
screening. Because of this, the preclinical phase depends not only on the biological
processes but also on the probability of cancer detection. Preclinical parameters are
estimated from indirect evidence using maximum likelihood estimation using the
Nelder-Mead algorithm. The MISCAN model includes 18 preclinical states, derived
from combinations of T-stages (T1, T2 and T3+), Gleason grade (well, moderately, and
poorly differentiated) and disease extent (loco-regional and distant). The cancer can
progress from each preclinical detectable state to clinical diagnosis, where the cancer is
diagnosed due to symptoms.
The screening is then superimposed on the simulated life histories. If a person has a
preclinical disease state the early detection could then alter a person’s life-history. The
screening tests are modelled by its sensitivity and there is no direct representation of PSA
in the MISCAN model. After clinical diagnosis, the MISCAN model uses stage and
treatment specific survival.
2.4.2 Michigan
The Michigan model is a statistical mixture model of prostate cancer incidence and
mortality [26, 27]. It was developed to analyse the US Surveillance, Epidemiology, and
End Results (SEER) population and cancer registry data. It is used to understand, predict
and optimise the population impact of cancer control processes in prostate cancer.
The model is composed of components by which predictions are made based on
population data. The incidence component takes population data as inputs and predicts
prostate cancer incidence by calendar year and age, both in the presence and absence of
PSA testing. The survival component also takes population data as an input and models
the relationship between a set of covariates (including age, year of diagnosis, cancer
7
stage and tumour grade) and a man’s survival prognosis.
2.4.3 FHCRC
The FHCRC prostate cancer model has been described previously [28, 29]. The model
includes prostate cancer onset as a function of age and continuous PSA growth with
random effects as a function of age, time from cancer onset and Gleason score. It also
includes clinical diagnosis and progression to metastatic cancer as a function of PSA as
well as survival as a function of treatment, Gleason score, extent and age. This is the
model that we extended and calibrated for the Swedish setting in Study II.
2.5 Cost-effectiveness of prostate cancer testing
Important modelling studies evaluating the cost-effectiveness of screening include the
Prostate Cancer Screening Options Appraisal that was done for the British National
Institute for Health and Care Excellence (NICE), in which clinical outcomes were
modelled using microsimulations [30]. The NICE assessment concluded that PSA
testing was not cost-effective.
More recently, Lao and colleagues [31] undertook a systematic review of
cost-effectiveness for prostate cancer screening using the PSA test. They concluded that
the cost per quality-adjusted life-year (QALY) was generally estimated to be over
$275,000USD, which was not cost-effective in most jurisdictions. Several recent
publications were not included in the review by Lao and colleagues, including
cost-effectiveness analyses by [3] and [32] , who found evidence that prostate cancer
testing could be cost-effective if carefully organised.
A NICE health technology assessment was undertaken for the Prostate Health Index
(PHI) and the prostate cancer antigen 3 (PCA3) test [33]. This careful assessment came
to the following conclusions: there were concerns with the precision of the PCA3
measurement; concerns with the storage and stability of the PHI samples; insufficient
evidence to establish the clinical thresholds for both tests; and the authors’
cost-effectiveness analyses suggested that neither test was cost-effective.
A recent review study concluded that although some model-based evaluations of
prostate cancer screening have been found cost-effective, the evidence is lacking [34].
The study further emphasised the need for country-specific data.
For Sweden, a recent cost-effectiveness analysis by the National Board of Health and
Welfare showed that PSA-testing for the ages 50–70 years would be cost-effective
compared with the current opportunistic testing [35, 36]. The study did not, however,
include the absence of PSA-testing as one of the comparators. It also assumed lower
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levels of compliance for urology visits and biopsies for the comparator with
opportunistic PSA-testing.
2.6 Modelling tools
Before we decided to develop the microsimulation R package, we reviewed the
available simulation frameworks. Microsimulation models have been used in economics,
demography and health; for a recent review of dynamic microsimulation models, see
[37]. Perhaps surprisingly, there are moderately few general frameworks for continuous
time microsimulations. One example is the proprietary MODGEN language, which is
developed by Statistics Canada [38]. The MODGEN language has been re-implemented as
an open source framework (Openm++, [39]), which uses different build tools.
Many discrete-event simulation (DES) frameworks and libraries focus on large,
process-oriented simulations, where events are modelled as a series of processes (e.g.
SimPy, JADES, and CSIM). In contrast, our task is focused on complex changes for a
small set of events, which are well suited for event-oriented simulations. Several
dynamic microsimulation models use a discrete time formulation (e.g [40, 41]). This,
however, is less efficient than continuous time for modelling rare events.
There are comparatively few DES libraries available for R [42]: simmer supports
process-oriented simulations, where the model is specified in R [43]; MILC models the
natural history model of lung cancer and MicSim implements simple microsimulations,
which are useful for teaching [44]. In contrast, R is frequently used for post-processing
[40, 45, 46]. There are few open source microsimulation models for cancer screening.
For health economics specifically, I have a recent and positive experience with the
heemod R package. The heemod package is a tool for health economic analysis with
Markov models [47]. The Markov framework is arguably better suited for smaller models,
where a detailed representation of the natural history is not required. Finally, the hesim
package for health economic simulation modelling shows promise. It allows for multiple
states with partitioned survival models and has a continuous time formulation [48]. The
package is relatively recent and under intense development, but could prove useful also
for more complex models.
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3 Materials
3.1 Data sources
Several data sources were used during this thesis, including the Stockholm PSA and
Biopsy Register (SBPR), the STHLM3 diagnostic trial, Prostate Cancer data Base
Sweden (PCBaSe), life-tables and aggregated data on prostate cancer incidence and
mortality (see Table 3.1).
The primary research database was the SBPR database [15], which consists of all men
who lived in Stockholm county during the period 2003–2016. The SBPR uses an
encrypted identifier to link to: PSA tests, including their PSA values (approximately
400,000 men with 1.5 million tests) and prostate biopsies (approximately 60,000
biopsies) from the laboratories serving the Stockholm county; the National Prostate
Cancer Register (NPCR, with 20,000 diagnoses) and the National Cancer Register,
where both databases have a coverage that is over 93% [49]; the Total Population
Register, including migration to and from the Stockholm county; inpatient and outpatient
hospitalisations; the National Death Register, including cause of death; and the
Prescribed Drugs Register. Using information from SBPR, we modelled for PSA test
uptake and re-testing, repeat testing following a negative biopsy, biopsy compliance and
biopsy accuracy.
From the STHLM3 trial, we got the relative true and false positive fractions for the
STHLM3 test for men with a PSA above a reflex threshold of 1 ng/mL from the baseline
publication [20]. We re-analysed the STHLM3 data to calculate true and false positive
fractions for reflex thresholds of 1.5 and 2 ng/mL, while keeping the STHLM3 threshold
at the same level as the baseline publication.
PCBaSe is a national research database that links the National Quality Registry for
Prostate Cancer (NPCR) with other health and population registers, including tumour
characteristics, primary treatment and survival. We used PCBaSe to model survival from
prostate cancer diagnosis by age, Gleason score, tumour extent and PSA values.
Period-based relative survival estimates were provided by PCBaSe at 10 and 15 years
after diagnosis for the period 1998–2014.
We also used aggregated data from life-tables provided by Statistics Sweden, and
incidence and mortality rates for prostate cancer provided by Socialstyrelsen.
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3.2 High performance Computing Resources
Microsimulation modelling of large populations can be computationally expensive. For a
rare event like prostate cancer deaths, one would need to simulate a large population in
order to contrast interventions (typically 106–108 individuals). Calibrating the model, i.e.
fitting to observed data, is a particularly computationally demanding procedure. To do
this, we used methods such as Nelder-Mead [50] and approximate Bayesian computation
[51].
To access sufficient computational resources, we used high-performance computers at
the Swedish Royal Institute of Technology’s Center for High Performance Computing.
This was facilitated through the Swedish e-Science Research Centre. These resources
allow for both shared and distributed memory parallelisation. Without this type of
resource, this project would not have been feasible.
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4 Ethical considerations
The data sources we use are described in the section Data sources. The parameter inputs
and calibration targets that we use for the model are derived from detailed individual-level
data. These data are potentially identifiable and their analysis has required the appropriate
ethical approvals. As part of those approvals, the data need to be securely stored and
publication of the findings should not identify individuals. To ensure this, we consider the
General Data Protection Regulation (GDPR), Swedish legislation and the KI rules in our
use of individual-level data.
In contrast, the synthetic simulations use summary inputs and summary calibration
targets, for which there are no ethical issues: the microsimulations are purely stochastic
and do not have any meaning for any real individual. The simulated individuals are
synthetic and are not sensitive data.
Another ethical aspect is our cost-effectiveness analysis, which uses measures such as
age and health specific quality of life (these can even be discounted). The quality of life
measure could be seen as a scalar for the value of a life-year, and is controversial in some
context (e.g. in the United States). The use of cost-effectiveness thresholds can also be
interpreted as setting a monetary value on life. Although these measures makes sense at
a population level, they can easily become offensive if interpreted at an individual level.
Care must be taken when communicating these type of results.
Besides aspects on security of personal level data and the communication of results,
there are also ethical aspects on conducting open and reproducible research. To do this
we have, as one of few, published our natural history model [52], and our articles are
written using literate programming.
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5 Methods
5.1 Screening dynamics
As may be evident from the Background section on PSA screening, the effects of
screening for prostate cancer are debated. The controversy is partly due to classic
challenges, such as whether a study assesses technical efficacy compared with real-world
effectiveness, or due to issues with study design, such as contamination of the control
arm. There are, however, inherent challenges in understanding screening because
empirical evidence is only partially observed for a dynamic system. A mathematical
formulation for screening was developed by Zelen and colleagues, with seminal articles
by Day and Walter [53, 54]. Using a simplified model, we assume a constant intensity
for latent, screen-detectable disease (e.g. I = 0.01), with an exponential time from
cancer onset to symptomatic detection (e.g. with a mean of ten years), we could imagine
screening at 55, 59, 63 and 67 years of age. The predicted incidence of symptomatic
diagnoses and the prevalence of latent, screen-detectable disease at each of the screens
are shown in Figure 5.1. We see that the incidence of symptomatic diagnoses and
prevalence of latent cancers decline with repeated screens. Note that this part of the
system is normally not observed and the incidence of clinical prostate cancer is expected
to increase at older ages.
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Figure 5.1: Simplified model for incidence and prevalence of pre-clinical disease
for screening at ages 55, 59, 63 and 67 years. Inspired by: [53]
A second challenge is that the merits of a screening program consists not only of
disease detection but also of the subsequent treatment and management. If one assumes
that the prognosis is determined by the stage at detection, this can be used to model
17
disease specific survival. If an earlier detection leads to a shift in the stage at diagnosis,
this can be used to model for a mortality benefit from screening [55]. However, if the
model includes too few stages then the survival effect may "lack in resolution", leading
to an under-representation of the survival benefit. This is the reason why we chose to
model for T-stages, grouped by T1–T2 and T3–T4. To illustrate how this can lead to
both overdiagnosis and treatment benefits, we constructed Figure 5.2. It shows two men:
at the top, there is a man with a screening benefit under two counterfactual life-lines; and
at the bottom, a man with an overdiagnosis under two counterfactual life-lines. As
described in the caption, this figure also describes three time periods (sojourn time, lead
time and delay time) that are specific to screening [53].
In summary, there are many factors that influence the effectiveness of early detection
of prostate cancer and only a few have been evaluated by controlled clinical trials. These
factors include the test characteristics, treatment modalities, population characteristics
and detection strategies. These factors can also interact to influence the effectiveness of
early cancer detection.
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5.2 Model taxonomy
A system can either be described analytically, with e.g. a system of equations, or as a
process implemented via a simulation model. If the system of interest is too complex to
solve analytically, the modeller may then need to use simulation. If the model has time
dependencies, the model is called dynamic; in contrast, a static (or steady-state) model
calculates the system in equilibrium [37]. If the model also represents uncertainties it is
called probabilistic or stochastic and if the model result is completely determined by its
initial conditions it is called deterministic. The modeller also needs to decide whether
to represent the modelled variables, including time, states and events, either as being
continuous or discrete. For discrete events, the model formulation can be either process-
oriented (when the events are modelled within a process), or event-oriented (when the
events are modelled separately). Lastly, the population can be modelled using groups or
using individuals.
For continuous time with discrete states, we can consider the transition intensities or
rates from one state to another to be dependent on age, which describes a Markov
process, or the rate may depend on the time in state, which describes a semi-Markov
process. For our purposes, we will use continuous time with discrete states, with a
combination of Markov and semi-Markov rates for individuals. This is a form of
microsimulation. In health sciences and the econometrics, these units are often
individuals and the microsimulation will generate stochastic life histories. We have
implemented this model within a framework for discrete-event simulation (i.e. no
changes in the system occur between consecutive events) using event-oriented
simulations [56].
To reduce the Monte Carlo error, we use random number streams for different
processes and use random number sub-streams for each individual, as proposed by Stout
and colleagues [57].
5.3 Calibration, validation and sensitivity analysis
The validity of the model is important if the model is going to provide useful predictions.
Some of the model parameters can be estimated directly from observable data. Examples
of this include PSA re-testing and biopsy compliance. However, other model parameters
are not directly observable. We can use calibration to ensure that the model parameters
reflect the available data. We can calibrate either by using maximum likelihood
estimation or Bayesian computations. Importantly, we can only observe part of the data
that we ideally would like to have and typically we fit models to observed marginal
distributions using indirect estimation [58] or approximate Bayesian computation [51].
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The approximate Bayesian computation (ABC) approach has the advantage of allowing
for prior (empirical) distributions for some parameters and, very usefully, sampling from
the posterior distribution.
Moreover, we can compare the predictions with available data for model validation. As
for calibration, this will often use observed marginal distributions, such as cancer rates by
age and stage, to assess whether the model predicts observed patterns.
Given the marked uncertainty in the model parameters, it is important to understand
how sensitive the predictions are to model assumptions. The classical approach in health
economics is to use probabilistic sensitivity analysis: prior distributions for parameters
are independently sampled 1000 times, and then predictions are recalculated to
demonstrate the effect of uncertainty on the parameters. A more computationally
efficient, yet challenging, approach is to take samples from the posterior distributions to
represent the parameter uncertainty, and use those samples to show uncertainty in the
predictions. Both of these approaches are computationally challenging. One alternative
approach used by cervical cancer screening modellers at Harvard is to perform a grid
search on the parameter space and keep the values that are close to the maximum
likelihood estimate using a likelihood ratio test [59].
5.4 Computational methods
5.4.1 Nelder-Mead
Nelder-Mead is numeric method for derivative-free function optimisation f : Rk → R
[50]. Nelder-Mead does not guarantee reaching a global optimum and therefore the point
of convergence may depend on the initial values. The algorithm first starts by calculating
a simplex, S. This is a geometrical shape, with k + 1 vertices for ∈ Rk. Then follows
a sequence of steps, which varies between implementations. Generally this sequence
involves ordering of vertices, calculating the centroid on the opposite side of the worst
vertex, and a transformation step. During the transformation step, the geometrical shape
of the simplex is changed and the proposed vertex is compared with the previous centroid
point. If the new point better optimises the function then the proposed point becomes
part of the new simplex. In Study II we used the Nelder-Mead algortihm provided in R’s
optim() function.
5.4.2 Calculating standard errors from the Hessian
The Hessian is a square matrix of the second-order partial derivatives of a scalar-valued
function with respect to its parameters. We focus here on the log-likelihood function l(θ)
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with variables θ . The derivatives describe the curvature of the function over variables
θi and θ j. The Fisher information can be expressed as I(θˆML), θˆML are the maximum
likelihood estimates, such that
I(θˆML) =
(
− ∂
2
∂θi∂θ j
l(θ)
)∣∣∣∣
θ=θˆML
, 1≤ i≤ k, 1≤ j ≤ k (5.1)
where k is the length of the vector θ .
The observed Fisher information can be found by minimising the negative
log-likelihood, and calculating the Hessian for the minimum. The standard error (SE) of
the estimate, can then be calculated by taking the square roots of the inverse of the
diagonal elements of the covariance matrix. For the ith value of θˆML, the standard error is
SE(θˆML,i) =
√
(I(θˆML)−1)ii (5.2)
Calculating analytical derivatives for our simulation model was not possible, due to
the nested random-effects and the hierarchical modelling of events. The Hessian were
calculated through numerical differentiation using finite differences.
Numerical differentiation based on simulations from a stochastic, and therefore
imprecise, function has some inherent challenges. Besides the obvious solution of
increasing the simulation size even further for a better signal-to-noise ratio, we benefited
from increasing the distance between the function evaluations, denoted ∆. As
exemplified in Figure 5.3, the stochastic variation makes it difficult to calculate the
partial derivatives for a ∆ where the stochastic variation is large in comparison to the
likelihood curvature.
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Figure 5.3: Example showing the challenge in numerically calculating the Hessian
with imprecise function evaluations from a stochastic model. The Hessian from the
left panel with a smaller ∆would not be consistent with a function optimum, whereas
the Hessian from the right panel with a larger ∆ would.
5.4.3 Markov chain Monte Carlo
The mechanism behind a Markov chain Monte Carlo (MCMC) is to construct and
simulate a Markov chain whose equilibrium distribution is the distribution we want to
sample from. A time homogeneous Markov chain will converge to a stationary
(equilibrium) distribution, independent of the initial parameter values.
The Metropolis-Hastings algorithm is an MCMC algorithm that, based on the current
location of the chain, picks a new candidate sample point, which then either is rejected or
accepted. New candidate sample points are picked using a proposal density Q(θ ∗|θ (t−1))
[60]. In Study IV the proposal density was a multivariate normal distribution whose
covariance matrix was estimated from a random sample of the parameter space in which
the target distribution was evaluated. The steps in the Metropolis-Hastings algorithm are
outlined as follows:
1. Propose a move to θ ∗ by drawing from q(·|θ), where θ is the current state.
2. Calculate r = pi(θ ∗)q(θ |θ ∗)/pi(θ)q(θ ∗|θ)
3. Move to θ ∗ with probability min(1,r), else stay at θ ; go to 1.
23
5.4.4 Approximate Bayesian Computations
In Bayesian inference, we are interested in either computing or sampling from the
posterior distribution of a set of parameters θ given data D generated from a model M.
The posterior distribution is deduced from the data likelihood P(D|θ) and a prior
distribution pi(θ):
P(θ |D) =P(D,θ)
P(D)
=
P(D|θ)pi(θ)
P(D)
∝ P(D|θ)pi(θ) (5.3)
To deduce, or simulate from, the posterior is not possible with the standard framework
if the data likelihoods are hard or impossible to compute. ABC was proposed to simulate
observations from posterior distributions without the use of likelihoods. It can also be
useful when a full Bayesian analysis is computationally heavy. The rejection sampling
version of ABC is summarized in the following steps [61]:
1. Generate θ from pi(·)
2. Simulate D′ from model M with parameter θ
3. Calculate a measure of distance ρ(S(D′),S(D)) between S(D′) and S(D), where
S is a summary statistic.
4. Accept θ if ρ < δε , and return to 1
For a given distance function ρ and a threshold δε , accepted observations are independent
and identically distributed from f (θ |ρ(S(D),S(D′))≤ δε) Ideally, S should be a sufficient
statistic for θ , otherwise the resulting posterior will only be an approximation of the true
posterior distribution [62].
5.4.5 ABC-MCMC
Although, rejection sampling in ABC is easy to implement and generates independent
observations, it can be very inefficient as the acceptance rate of the samples is low [62].
Instead, a MCMC approach has been proposed in connection with ABC [61]. The method,
outlined below, is based on the Metropolis-Hastings algorithm where q(θ ∗|θ (t−1)) is a
proposal distribution.
1. Propose a move to θ ∗ by drawing from q(·|θ), where θ is the current state.
2. Simulate data D′ using model M and parameters θ .
3. If ρ(S(D′),S(D))< δε , go to 4, else stay at θ and return to 1.
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4. Calculate r = pi(θ ∗)q(θ |θ ∗)/pi(θ)q(θ ∗|θ)
5. Move to θ ∗ with probability min(1,r), else stay at θ ; go to 1.
Various improvements to the ABC-MCMC approach have been proposed, including
transformations of the summary statistics S [62] and ABC regression adjustments [63].
5.5 Cost-effectiveness analysis
To provide evidence to policy makers for deciding on which cancer screening
interventions are most suitable, it is common to undertake a health economic evaluation.
An evaluation that compares the lifetime expected costs and lifetime expected health
utilities for different interventions is called a cost-utility analysis or a cost-effectiveness
analysis. For a screening intervention k, the expected values for the effectiveness and
costs can be calculated by simulating the life histories for i = 1, . . . ,n individuals and
then calculating the average, such that:
Effectivenessk =
1
n
n
∑
i=1
∫ ∞
0
dUik(t)
(1+δ )t
Costsk =
1
n
n
∑
i=1
∫ ∞
0
dCik(t)
(1+δ )t
where we have time dependent cumulative utilities Uik(t) and cumulative costs Cik(t) for
person i, where δ is the discounting rate (e.g. δ = 0.03). The costs and utilities are
typically taken from reviews of the literature or analyses of register data. The costs can be
taken from a health sector or societal perspective and the utilities can be calculated using
years of life lost or using quality-adjusted life-years.
For decision analysis, two scenarios can be compared using an incremental
cost-effectiveness ratio (ICER). The ICER is a ratio of the cost difference and the
effectiveness difference from the compared scenarios. For a plot of the effectiveness
against the costs, the convex hull of values provides a cost-effectiveness frontier, which
suggests which scenarios or combination of scenarios are most effective given a
cost-effectiveness threshold [64].
For Study III, costs were taken from a review by the Swedish National Board of Health
and Welfare, as described in the section Cost-effectiveness of prostate cancer testing [36];
see the full paper for details. The cost inputs for this study were largely based on the
southern region in Sweden. Particularly influential costs, e.g. the cost of a biopsy, were
compared with the cost per patient for diagnosis-related disease groups ("N75O manliga
genitalia px O", [65]).
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Health state values were taken from a review by Heijnsdijk and colleagues [66]. These
values combine evidence from different populations using different study designs and
instruments.
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6 Summary of the results
In summary, we provide evidence, methods and tools for planning cancer screening. In
Study III, we present evidence for policy planning of prostate cancer screening in
Sweden. By using the microsimulation framework from Study I and the natural history
model from Study II we performed a cost-effectiveness analysis of the STHLM3 test.
Leveraging our experiences from Study II, we present a method for calibrating
microsimulation models in Study IV.
6.1 Study I
In Study I, we presented our parallel discrete-event microsimulation R package. We
motivated our design choices, such as the use of Rcpp for speed, the SSIM library for
handling events and the RngStreams library for common random numbers. We also
investigated how the simulations could be mapped onto several processor cores followed
by a reduction operation to collect the results in a single report. We investigated the
efficiency of four alternative implementations, specifically using R’s parallel package,
OpenMP, MPI using the Rmpi package and a hybrid implementation using both OpenMP
and MPI. While simulating a cohort of 107 individuals, we measured the speed for all
implementations on a single compute node and for the distributed memory
implementations, MPI and OpenMP/MPI, on up to 16 nodes. We observed close to linear
scaling for all implementations within a compute node. MPI was the fastest
implementation for the first three nodes. The hybrid OpenMP/MPI continued to scale,
also after the first three nodes, until approximately 10 nodes and at 16 nodes and 128
cores it had an efficiency of approximately 25%. Finally, we showcase the use of the
microsimulation package with a case study.
Besides the scientific publication, an equally important output of Study I is the
software. The microsimulation R package allows other researchers with an interest in
modelling cancer screening to leverage these features. However, the flexibility and speed
comes at the price of accessibility. This package targets modellers who are willing to
specify their models in C++ using the provided classes and methods. Whereas the
original FHCRC code, was written in C with little to no abstraction of the simulation
framework. In contrast, we provide a framework, readily available, for modellers
wishing to investigate cancer screening and its cost-effectiveness using microsimulation.
The microsimulation R package is open source and available under a GNU General
Public License (GPL) 3 license at:
https://github.com/mclements/microsimulation
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6.2 Study II
For Study II, we adapted and extended the FHCRC prostate cancer screening model.
The model simulates PSA growth together with individual life histories, including cancer
onset, and progression from localised to metastatic disease by Gleason score. Using the
SBPR and PCBaSe databases, we included additional T-stages and Gleason grades in the
model. We also calibrated the survival by PSA, M-stage, Gleason grade and age. Using
results from ERSPC, we calibrated the model to the reported incidence rate ratio (IRR)
and validated the model against the reported mortality rate ratio (MRR). We also used
Swedish prostate cancer incidence and mortality rates for validation.
We also predicted the effects of dynamically changing the current opportunistic PSA
testing pattern for regular PSA screening. We predicted a reduction of the prostate
cancer incidence with an IRR 0.86 (95% Monte Carlo Interval (MCI): 0.86–0.86) and an
increase of prostate cancer mortality with a MRR of 1.02 (95% MRR: 1.01–1.02), when
introducing 8-yearly screening in men aged 55–69 over 20 years.
The resulting natural history model, "Prostata", is in itself an important output of
Study II. The Prostata model is available as an R package for modelling prostate cancer
screening for Sweden. The R user can change hundreds of parameters and simulate 18
different screening scenarios. The prostata R package can be used to provide evidence
on cost-effectiveness of prostate cancer screening in Sweden.
The prostata R package is available under an open source (GPL 3) license at:
https://github.com/mclements/prostata
6.3 Study III
We investigated the cost-effectiveness of the STHLM3 screening test for prostate cancer.
The test uses blood analysis of proteins, a genetic risk score and clinical variables to test
for prostate cancer. The test process for STHLM3 includes: first a PSA test; men with
a PSA above a reflex threshold (1 ng/mL in the trial) had their risk for Gleason ≥ 7
predicted, and finally men with a risk above 10% were referred to a urologist who after a
digital rectal exam could perform a biopsy. For men with PSA between 3 and 10 ng/mL,
this process reduced the number of benign biopsies by 44% (95% confidence interval
(CI): 35–54%) and the number of biopsies resulting in a Gleason 6 cancer by 17% (95%
CI: 7–26%), while maintaining the same number of Gleason 7+ cancers. We used the
reported results for a reflex threshold of 1 ng/mL and we re-analysed the STHLM3 trial
data for reflex thresholds of 1.5 and 2 ng/mL.
Using the natural history model from Study II, we predicted that PSA testing every four
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years would result in 71 fewer deaths and 652 more life-years per 10,000 men, compared
with no screening. When using the STHLM3 test at a reflex threshold of 1.5 mg/nL, we
predicted 4 more deaths and 22 fewer life-years, but also a reduction in biopsies by 2235
per 10,000 men. This results in a slight increase of 4 QALYs for 10,000 men, compared
with PSA testing.
We also evaluated the cost-effectiveness of the STHLM3 test under a four yearly
screening program for ages 55–69 year. The STHLM3 test was more cost-effective at
higher reflex thresholds when comparing to PSA testing. At reflex thresholds of 1, 1.5
and 2 ng/mL the STHLM3 test had ICERs of 170,000, 60,000 and 5000 EUR/QALY,
respectively.
The STHLM3 test, when used as a reflex test for PSA ≥ 2.0 ng/mL, was predicted to
have a low cost per QALY compared with PSA testing for Sweden. However, using the
STHLM3 test for lower reflex thresholds was predicted to have high costs per QALY for
Sweden.
6.4 Study IV
For models to be useful, they need to be calibrated against observed data targets. This
calibration may be difficult for calibration targets on different scales and when data
likelihoods are not available. In Study IV, we propose a method for addressing some of
the challenges we experienced in Study II. Our methods incorporate ABC within a
standard Bayesian framework to allow for calibration to data with partially unknown
likelihoods. We then use MCMC for sampling from the posterior distribution. For
calibrating the model described in Study II, we needed to set acceptance regions for
some of the calibration targets.
We compared our suggested ABC hybrid method with a full ABC approach and the
likelihood approach with quadratic constraints presented in Study II. We found that the
full ABC approach with a negative log-likelihood cut-off of 450 did not, as expected,
optimise the likelihood well. The likelihood approach with quadratic constraints did
optimise the likelihood better, with resulting negative log-likelihood of 302, but required
somewhat arbitrary scale factors for the quadratic scale factors. Initially, we experienced
difficulties in sampling from the parameter space with the ABC-hybrid method, due to
sharp peaks in the likelihood. We solved this by scaling the likelihood before sampling
and then re-weighting the posterior distribution. For the ABC-hybrid we reached a
negative log-likelihood of 270, while fulfilling the other constraints. The benefits of the
ABC-hybrid method came at the cost of increased computational requirements.
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7 Discussion
The question on how to screen for prostate cancer has proven to be challenging, which
motivates the use of more complex models. However, these models rely on assumptions
whose validity should be assessed. The evidence we provide should, therefore, be
considered together with evidence from other modelling studies and the controlled trials.
One of the challenges with microsimulation modelling is assessing whether the model
is valid for a specific research question. We have spent considerable time improving the
model to evaluate the cost-effectiveness of the STHLM3 test. For the STHLM3 test, we
extended the FHCRC model to include more detailed modelling of Gleason scores. Our
subsequent fitting of survival under current screening to the NPCR also led to a marked
improvement in the modelling of differential survival. We further improved the survival
model by allowing for T stages in the natural history model. The question remains: how
do we know whether we have a good model for prediction? Moreover, a further challenge
is how to validly represent uncertainty for a large and complex model, as outlined in
Study II and Study IV.
7.1 Limitations
There are several important limitations of our approach. First, survival may not fully
represent the more recent Gleason grading, where the longer-term survival was
represented by cases from the late 1990s. Conversely, it would have been useful to have
good survival data from an unscreened population, however data on Gleason grading
prior to 1998 were not systematically collected and any such data would be based on
older Gleason grading. Second, the model is not well calibrated at older ages. This
limitation leads to difficulties in the interpretation of the epidemiological outcomes over
a life-time (e.g. over-diagnosis and prostate cancer deaths). Third, register data are often
less reliable at older ages, including cause of death in older men. Fourth, our modelling
of the effectiveness of prostate cancer testing is critically dependent on one trial
(ERSPC). If the point estimates for the incidence and mortality rate ratios for PSA
testing are biased, then our predictions will also be biased.
Fifth, we have assumed that policy should be based on out-of-sample predictions from
the observed randomised trial to life-time predictions. From our model, the short-term
estimates of costs and effectiveness are qualitatively different to the life-time predictions.
Consequently, the choice of time-line will lead to different conclusions. However, we also
know that the long-term predictions are imprecise and possibly biased.
Sixth, from Study III, there is an extensive discussion on the uncertainty in the cost
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inputs, particularly for the biopsies. There are substantial discrepancies between the listed
outpatient price in Stockholm and the price used in the governmental report [36], which
in turn is similar to the national reimbursement provided to the hospital. We decided to
base our costs on the government report and addressed this uncertainty in a sensitivity
analysis. This uncertainty warrants further investigation.
Seventh, there is uncertainty in the health state values used for Study III. The health
state values were developed by Heijnsdijk and colleagues [66] and are frequently cited.
However, the original estimates of the health state values were based on multiple
instruments with different study designs from multiple populations.
7.2 Strengths
Our approach has a number of strengths. We started out with a prostate cancer natural
history model that was well validated in the US population. Using the detailed Swedish
health and population registers, we carefully extended and calibrated the model. Using
those contemporary data, we expect that the calibrated model will represent the effects of
modern diagnostic procedures and treatment well. Our model is particularly well suited,
and arguably the best model available, to the evaluation of reflex tests, such as STHLM3
and the Prostate Health Index test.
We have aimed to follow the International Society of Pharmacoeconomics and
Outcomes Research (ISPOR) guidelines for DES outlined by Karnon and colleagues
[67]. Particularly important best practices we use are: stochastic modelling of
time-to-event as fixed times in the disease states could easily be misleading when
designing screening policies; we do not solely rely on guidelines but use observed
clinical practice from SBPR; we take life-time perspective with continuously modelled
risks of disease progression and other cause death; we use variance reduction techniques
such as common random numbers; and we quantify uncertainty using a probabilistic
sensitivity analysis.
Finally, we used some of the target data for validation rather than calibration. For
example, prostate cancer incidence and mortality rates were used for validation. Those
data would probably aid in any improvement of the model calibration, however our
approach provides a more objective evaluation of the model validity.
7.3 Our contribution to open science
The development of a natural history model represents a considerable effort by the
investigators. It is therefore tempting for researchers to not make their models open and
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available to others. This can be motivated by arguing that a closed source model,
financed through occasional consultancies, allows for more development resources and
better control of the model development and its use.
On the other hand, such a model is difficult for other researchers to validate and could
be critiqued for being a "black box". It is also not clear to us, that a closed model will
develop better over time. We are grateful towards Ruth Etzioni and Roman Gulati for
sharing the original FHCRC model with us. The choice to extend upon the FHCRC
model was simple: it was the only open source CISNET model. Continuing on this path,
we have released both the microsimulation and prostata R packages under an open
source license, with the hope that others might use, validate and extend them.
7.4 Generalisability
We have experience with comparing and adapting one natural history model to the
Swedish setting. The uncalibrated model did not represent incidence, mortality or
survival well. This could be due to differences in the Swedish population or perhaps in
part due to more detailed data.
In theory there is a clear distinction between model structure and model inputs.
However, for these extensive models, some inputs are not easily available, e.g. cancer
onset distributions, in what is otherwise a data-rich setting. The model generalisability is
therefore confounded by those uncertain data inputs.
We have made several adaptions and extensions of the Prostata model to better
represent prostate cancer in Sweden. Most of those model inputs can be easily replaced,
e.g. the PSA threshold of 3 ng/mL, treatment patterns, biopsy compliance patterns, and
the population structures. Other parts, such as calibrated parameter values, would require
detailed data and there would be some effort to re-calibrate the model for a new context.
The cost-effectiveness analysis of the STHLM3 test in Study III was performed from
the Swedish context, where the natural history model, the cost inputs and the background
health state values were specific to Sweden. Interpretations for other countries should be
done with caution.
7.5 The right tool for the job
Cancer screening is a complex process, where latent processes and lead-time bias make
attempts to simplify the model structure more prone to errors. The lack of contemporary
untested populations further complicates attempts to understand the screening effects.
Nevertheless, evaluations of cancer screening for the Swedish National Board of Health
33
and Welfare have often been performed using simpler deterministic, so called "cohort",
models. Although this model structure may be useful for transferring directly observed
trial results to the Swedish population structure, any extrapolation would rely heavily on
assumptions. The accuracy of these simpler models remain unclear, since they are not
available for validation by other researchers.
The question of model complexity is also interesting on a more philosophical level.
The main use of these models are out-of-sample predictions, e.g. life-time risk, novel
tests or altered testing patterns, which are difficult to validate against data. Instead they
rely on the assumption that the modelled mechanistic properties remain similar also for
the extrapolation.
7.6 Concluding remarks
Microsimulation modelling of the natural history of prostate cancer is computationally
and scientifically challenging. It requires detailed data and an understanding of the
healthcare pathways as well as statistical and computational resources. Once a model is
well calibrated to a population it can be used for answering questions on detection,
diagnosis and treatment. In particular, early detection is difficult to model in other ways.
This thesis describes the development of tools and methods for microsimulation
modelling for cancer screening in general, and prostate cancer screening in Sweden in
particular. We provide predictions for the dynamic effects on prostate cancer incidence
and mortality in Sweden, should screening be introduced with the current opportunistic
PSA testing patterns as a baseline. Prostate cancer screening has been assessed many
times, in many countries, but remains an open question.
Assessing the prediction uncertainty is a difficult task. Ideally, model assumptions
should be investigated on a larger scale by multimodel initiatives like CISNET. The
comparative modelling by CISNET may, at least in its earlier years, have described
uncertainty in the model assumptions. However, longer-term collaborations may lead to
cross-pollination between the models, where the predictions from the different models
are more precise (i.e. lower variance), but there may be shared bias across the models.
Assessing the uncertainty in model inputs is more easily done. This could be done
either by deriving the standard errors from the Hessian as in the probabilistic sensitivity
analysis in Study III (partly based on the standard errors from Study II) or using the
methods we develop in Study IV.
One way to address the question of early detection of prostate cancer is to use a test
with a higher specificity, e.g. the STHLM3 test. We investigated the cost-effectiveness of
the STHLM3 test, at its current price, and found it cost-effective if used in a group with
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higher risk. Specifically, the STHLM3 test was found cost-effective when used as a reflex
test following a PSA of 2 ng/mL, but not when used after a PSA of 1.5 ng/mL or lower.
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8 Future perspectives
8.1 Other applications for the Prostata model
Given its careful calibration and validation, the Prostata model is now well suited to
answer a range of other research questions. In particular, we plan to assess the
cost-effectiveness of magnetic resonance imaging (MRI) at a urological consultation
prior to a prostate biopsy and in combination with an MRI-guided biopsy. Moreover,
there is considerable interest in whether MRI will be cost-effective when combined with
the newer prostate cancer screening tests.
Sweden uses a lower PSA threshold than many other countries. In Sweden, a PSA
threshold of 3.0 ng/mL is used for men below age 70, without familial risk. In contrast
e.g. the United States uses a PSA threshold of 4 ng/mL. One interesting question would
be to investigate how this policy choice affects the effectiveness and costs of testing with
PSA. Another question of interest would be to investigate how the STHLM3 test would
perform in comparison to a PSA threshold of 4 ng/mL.
8.2 Potential model structure development
For the Prostata model to represent the tumour biology as well as possible, some future
development could be considered.
First, we could incorporate more detailed modelling of tumour size and extent of
spread. One approach would be to include further T-stages. Second, we could investigate
whether the model predictions are affected by Gleason de-differentiation. There has been
some debate in the literature as to whether the Gleason grade is largely fixed at cancer
onset or whether it de-differentiates with time following cancer onset. De-differentiation
is not directly observable, Gleason scores are imprecisely measured, and the modelling
and indirectly observed evidence is inconclusive [68]. Third, we would like to merge
more recent changes for the FHCRC model into the Swedish Prostata model, including
changes to the onset distribution and the shape of cancer survival. Fourth, we could
revise the PSA sub-model using the PSA values available from the SBPR. Fifth, we
could investigate the accuracy for the symptomatic diagnoses in the older ages, also
using SBPR.
We also see an opportunity for inputs from the Prostata model to be incorporated back
into the CISNET prostate cancer models. In particular, the Swedish data on Gleason
scores and prostate cancer survival are more contemporary than data from the US SEER
registries.
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8.3 Applications to other domains
The simulation framework is well suited to moderately complex disease modelling.
Candidate diseases for the framework could include: breast cancer, using detailed natural
history models developed by Keith Humphreys and colleagues [69]; cervical cancer
screening, to take advantage of the National Cervical Cancer Register; and models of
diabetes care.
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9 Sammanfattning på svenska
För att kunna basera riktlinjer inom vården på evidens, måste man ibland utvärdera
interventionerna med hjälp av modeller. Valet av hur komplex en modell bör vara är en
avvägning, där en enklare modell kan vara lättare att beskriva och kalibrera, medan en
mer komplex modell bättre kan representera sjukdomsdynamiken och leda till mer
giltiga prediktioner. Att modellera riktlinjer inom vården är en tvärvetenskaplig uppgift,
som kräver kunskap inom flera discipliner t.ex. epidemiologi, medicin, biostatistik,
hälsoekonomi och datavetenskap.
Detta illustreras i Studie III, där vi företog oss att bedöma kostnadseffektivitet hos ett
nytt test (STHLM3-testet) för tidig upptäckt, s.k. screening, av prostatacancer. STHLM3-
testet använder en kombination av biomarkörer och självrapporterad data för att förutsäga
risken för prostatacancer. STHLM3-testet kan användas som ett reflextest efter ett PSA-
test. För att kunna avgöra hur väl testet fungerar för screening av prostatacancer, behövde
vi en modell av naturalförloppet hos prostatacancer. Modellen användes sedan till att
prediktera korta och långsiktiga effekter av olika screeninginterventioner.
För kunna göra detta utvecklade vi först, i Studie I, ett ramverk för att simulera
diskreta händelser med kontinuerlig tid i R och C++. I ramverket ingår bland annat
hantering av gemensamma slumptal för att minska Monte Carlo-felet och detaljerade
rapporter för hälsoekonomiska utvärderingar. I Studie II utökade vi en existerande
amerikansk modell av naturalförloppet hos prostatacancer. Vi använde svenska indata
för bland annat PSA-tester, diagnoser av prostatacancer, behandling, vårdförlopp och
överlevnad. Kalibreringen av naturalförloppet inkluderade båda PSA-testade och icke
testade svenska populationer. Till att börja med kalibrerade vi "Prostata" modellen
genom att maximera en likelihood tillsammans med icke-linjära restriktioner. Efter det
har vi i Studie IV, utvecklat en metod baserad på approximativa Bayesianska
beräkningar och Markovkedje-Monte Carlo metoder. Vår metod använder ett mer
systematiskt tillvägagångssätt för att väga samman bevis på olika skalor och drar
samtidigt nytta av de likelihoods som är tillgängliga. I Studie III inkluderade vi mått på
kostnader och livskvalitet och beräknade förväntad livslängd och kostnader under en
livstid för olika screeninginterventioner. Vi fann att STHLM3-testet var
kostnadseffektivt i Sverige om det används som ett reflextest för PSA högre än 2 ng/ml.
En lärdom är att mikrosimulering är både en beräkningstung och vetenskapligt
utmanande uppgift, särskilt för kalibrering och känslighetsanalyser. En annan är att,
ironiskt nog, så gör detaljrikedomen i de svenska sjukvårdsregistren att det är lätt att hitta
brister i modeller som är välvaliderade i andra populationer. Svenska data har därför
potential att förbättra de redan befintliga modellerna för cancerscreening.
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Styrkor i vårt tillvägagångssätt är: ett flexibelt, snabbt, skalbart och öppet ramverk för
att utveckla riktlinjer inom cancerscreening; vi har kalibrerat modellen av
naturalförloppet till nuvarande svensk incidens och överlevnad noggrannare för
Gleasongrader, medan de flesta andra modeller har kalibrerats till äldre, PSA-naiva
populationer; vi har införlivat detaljerad information och dragit bästa möjliga nytta av de
tillgängliga svenska sjukvårdsregistren. Begränsningar i vårt tillvägagångssätt är:
osäkerhet kring storleken på effekten som screening har på dödligheten i prostatacancer;
osäkerhet i validiteten av prediktionerna utanför observerade data och osäkerhet i hur
korrekta livskvalitetmåtten är. I framtiden planerar vi att använda Prostata-modellen för
att utvärdera användandet av magnetisk resonanstomografi i kombination med nya
screeningtest för prostatacancer.
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